Links
- ORCID
- ORCID
- Crossref | PDF
- [www.malariajournal.com] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
- [researchonline.lshtm.ac.uk] | PDF
- [europepmc.org] | PDF
- [www.researchgate.net] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
Tools
Adherence to prescribed artemisinin-based combination therapy in Garissa and Bunyala districts, Kenya.
,
Dejan Zurovac,
Laura O'Reilly,
Sarah Hoibak,
Alice Cowley,
Stephen Munga,
John Vulule,
Elizabeth Juma,
Rw Snow ,
Richard Allan
Abstract
Abstract Background Following the development of resistance to anti-malarial mono-therapies, malaria endemic countries in Africa now use artemisinin-based combination therapy (ACT) as recommended first-line treatment for uncomplicated malaria. Patients' adherence to ACT is an important factor to ensure treatment efficacy, as well as to reduce the likelihood of parasite resistance to these drugs. This study reports adherence to a specific ACT, artemether-lumefantrine (AL), under conditions of routine clinical practice in Kenya. Method The study was undertaken in Garissa and Bunyala districts among outpatients of five government health facilities. Patients treated with AL were visited at home four days after having been prescribed the drug. Respondents (patients ≥ 15 years and caregivers of patients